^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JCAR014

    i
    Other names: JCAR014, anti-CD19-4-1BB-zeta modified CAR CD8+ central memory and CD4+ T lymphocyte therapy, autologous anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T lymphocytes, CD19 fully human scFv CAR T cell therapy
    Company:
    BMS, Fred Hutchinson Cancer Center
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs: